Sabra Health Care REIT (SBRA) fundamentals: P/E, valuation, undervalued?
Sabra Health Care REIT · Real Estate · ref. ETF XLRE · price $19.31
In short — Sabra Health Care REIT trades at 77.2× earnings (P/E), 23.8× forward, with a net margin of 7.6 % and revenue growth of +25 %. Read: Cheap for the growth (P/E 24 for ~25% growth (PEG 0.9)).
Is Sabra Health Care REIT stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$19.31+9.5% over range
Oct 14, 25low $17.23 · high $22.39Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
30% recommend buying · 10 analysts
Valuation : Cheap for the growth — P/E 24 for ~25% growth (PEG 0.9)
Valuation
77.2
P/E (price/earnings)
23.8
Forward P/E
—
PEG
1.8
Price/book (P/B)
$4.9B
Market cap
0.25
EPS
Profitability & growth
7.6 %
Net margin
+25 %
Revenue growth
—
Earnings growth
$2.6B
Total debt
Sabra Health Care REIT income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $625M | $-78M | -12.4 % |
| 2023 | $648M | $14M | 2.1 % |
| 2024 | $703M | $127M | 18.0 % |
| 2025 | $775M | $156M | 20.1 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Sabra Health Care REIT's P/E and is the stock undervalued? What's a good P/E?
Sabra Health Care REIT's P/E is 77.2 (forward 23.8). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Sabra Health Care REIT profitable?
Sabra Health Care REIT has a net margin of 7.6 % (EPS 0.25). The company is profitable.
Is SBRA stock expensive?
Our read: "Cheap for the growth" — P/E 24 for ~25% growth (PEG 0.9). Cross-check with growth and sector.
💬 A question about Sabra Health Care REIT? The JPI assistant answers using our backtest data.
Keep exploring Sabra Health Care REIT